Last reviewed · How we verify

NCT04558385

Seroconversion in COVID-19 Recovered Population

Completed Last updated 1 April 2021
What this trial tests

trial testing IgG SARS CoV2 in Covid19 in 275 participants. Completed in 31 March 2021.

Timeline
1 July 2020
Primary endpoint
31 March 2021
31 March 2021

Quick facts

Lead sponsorLahore General Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment275
Start date1 July 2020
Primary completion31 March 2021
Estimated completion31 March 2021
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Lahore General Hospital

Who can join

Eligibility, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigate the kinetics of IgG responses to both N and S proteins in the subjects who suffered from COVID 19 and then had recovered.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Lahore General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04558385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing